During normal mammary gland development, s-SHIP promoter expression marks a distinct type of mammary stem cells, at two different stages, puberty and early mid-pregnancy. To determine whether s-SHIP is a marker of mammary cancer stem cells (CSCs), we generated bitransgenic mice by crossing the C3(1)-SV40 T-antigen transgenic mouse model of breast cancer, and a transgenic mouse (11.5kb-GFP) expressing green fluorescent protein from the s-SHIP promoter. Here we show that in mammary tumors originating in these bitransgenic mice, s-SHIP promoter expression enriches a rare cell population with CSC activity as demonstrated by sphere-forming assays in vitro and limiting dilution transplantation in vivo. These s-SHIP-positive CSCs are characterized by lower expression of Delta-like non-canonical Notch ligand 1 (DLK1), a negative regulator of the Notch pathway. Inactivation of Dlk1 in s-SHIP-negative tumor cells increases their tumorigenic potential, suggesting a role for DLK1 in mammary cancer stemness.
INTRODUCTION
Breast cancer is the leading cause of cancer-related death among females across the world. It is a highly complex disease marked by genetic and clinical heterogeneity (Torre et al., 2015) . Intertumoral heterogeneity of breast cancers led to a classification into several subsets with varied patient outcomes and implications for treatment. This heterogeneity is associated with an epithelial hierarchy in tumors resembling that observed in normal mammary gland. On top of this hierarchy that forms the tumor bulk is a cell subpopulation described as cancer stem cells (CSCs) or tumor-initiating cells (TICs) (Al-Hajj et al., 2003; Ginestier et al., 2007) . CSCs are defined as cells that retain extensive self-renewal potential through a series of generations and have the ability to recreate the heterogeneity of the original tumor through asymmetric division (Nassar and Blanpain, 2016) . The nature of breast CSCs is complex, with the demonstration of their heterogeneity both within and between breast tumors and the discovery of their plasticity (Sreekumar et al., 2015) . Strong evidence has suggested that they are responsible for the recurrence, metastasis, and drug resistance of high-grade tumors (Peitzsch et al., 2017) . A better understanding of breast CSCs might, therefore, provide prognostic information for relapse and metastasis and lead to the development of more efficient therapies.
Genetically engineered mouse models have been extremely important in helping to elucidate the mechanisms of pathogenesis of breast cancer (Menezes et al., 2014) . Different CSC subpopulations have been identified in these transgenic mouse models of mammary carcinogenesis using combinations of cell-surface markers, such as Lin À
CD29
hi CD24 hi (Zhang et al., 2008) , Thy1 + CD24 + (Cho et al., 2008) , CD29 hi CD24 med (Shafee et al., 2008) , and CD61 (Vaillant et al., 2008) . However, most of the sorting schemes require multiparameter fluorescence-activated cell sorting (FACS), yield sometimes rather heterogeneous cell populations, and are unclear in their biological meaning (Medema, 2013) . Due to the general lack of unique cell-surface markers, the development of new markers to prospectively identify putative CSCs is of the utmost importance (Brooks et al., 2015) . Stem cell-specific expression of s-SHIP (stem-SH2-containing 5 0 -inositol phosphatase) was initially identified in embryonic and hematopoietic stem cells (Tu et al., 2001) . A transgenic mouse (Tg 11.5kb-GFP or s-SHIP-GFP) was generated using the 11.5-kb s-SHIP promoter that specifically expresses enhanced green fluorescent protein (GFP) in several stem cell populations during embryonic development, including skin epidermis, hair follicles, mammary gland, and prostate (Rohrschneider et al., 2005) . In the mammary gland, s-SHIP/GFP labels puberty cap cells and pregnancy basal alveolar bud cells, with a stem cell potential (Bai and Rohrschneider, 2010 ). Notably, s-SHIP expression in cap cells is associated with the expression of Par3-like polarity protein, which is essential for mammary stem cell maintenance (Huo and Macara, 2014) . The C3(1)/SV40 T-antigen transgenic mouse model (Tg C3(1)-Tag mice) develops mammary hyperplasia by 3 months of age with subsequent development of mammary adenocarcinoma by 5-6 months of age (Maroulakou et al., 1994) . C3(1)-Tag mouse is a murine model of human basal-like breast cancer, a complex group of breast cancers with both basal and luminal features (Dontu and Ince, 2015; Gusterson and Eaves, 2018) . Using a cross-species genomics approach, murine expression profiles were compared with human breast cancers. The vast majority (z90%) of the C3(1)-Tag mammary tumors displayed characteristics of human basal-like breast cancer, and 5%-10% showed the claudin-low subtype feature (Herschkowitz et al., 2007; Pfefferle et al., 2013; Usary et al., 2016) , demonstrating the model's strong resemblance to human disease.
Here we aim to assess whether s-SHIP promoter expression could enable the isolation of a subpopulation of tumor cells with CSC characteristics, i.e., higher ability to self-renew and to form spheres in vitro, and higher ability to form secondary tumors phenotypically similar to the primary tumor, following their transplantation into immunodeficient mice. By crossing Tg 11.5kb-GFP mice with Tg C3 (1) Figure 1B ) and by flow cytometry after enzymatic digestion of tumors ( Figure 1C ) (1.03% ± 0.64% of total cells, n = 10). Figure 1B ). Importantly, GFP + tumor cells expressed K14 ( Figure 1B ). Similarly to s-SHIP/GFP expression at puberty during normal mammary gland development (Bai and Rohrschneider, 2010) , some K14 + mammary basal cells of 7-week-old bitransgenic mice also expressed GFP (Figure S1B ). We next examined the expression of cell-surface markers historically associated with stem/progenitor cells in the mammary gland. Previous studies using flow cytometry to isolate mouse mammary stem cells have shown the majority of these cells to have a CD49f Figure S2D ). Flow cytometry analysis of secondary tumors generated by Lin À CD49f + GFP + cells injected into SCID mice showed that the expression patterns of cell-surface markers were similar to those of the original tumor ( Figure 3B ). Interestingly, GFP + cells were also present in these secondary tumors ( Figure 3B ). The percentage of GFP + cells in secondary tumors was higher but not significantly different (Figure 3C Figure 4B ) (Table S1) . Granzyme E (GZME) was significantly upregulated in Lin and investigated the outcome of Gzme silencing on the sphere-forming potential of these cells. As shown in Figure S3C , the downregulation of Gzme did not affect the sphere-forming potential of GFP + cells. We were then interested in the Delta-like non-canonical Notch ligand 1 (Dlk1) gene that was significantly downregulated in Lin À CD49f + GFP + cells (fold change of 4.5) (Figure 4B ). Dlk1 gene encodes for a single-spanning transmembrane protein in the epidermal growth factor-like family, which includes NOTCH receptors and their ligands (Tanimizu et al., 2003) . DLK1 is a non-canonical Notch ligand and has been shown to act as an inhibitor of Notch signaling in vitro (Nueda et al., 2017) . Microarray analysis revealed the expression of Notch1, Notch3, and Notch4 genes in Lin confirmed by qRT-PCR using total RNA isolated from these two subpopulations. Similar to microarray results, we observed a fold change of 11 ± 8 ( Figure 4C , n = 4 different tumors). We thus delivered siRNA to knock down Dlk1 expression in Lin À CD49f + GFP À cells and performed sphere-forming assays. Lin
tion was transfected with siDlk1 or siScramble (siScr) and then cultured in serum-free sphere medium under nonadherent conditions for 7-10 days. A transient downregulation of Dlk1 expression was obtained with 77% of inhibition after 2 days of culture, and only 10% of inhibition in the generated spheres at day 8 ( Figure 4D ). We observed a significant increase of the sphere-forming potential of siDlk1-treated cells (0.82% ± 0.21%) compared with siScr-treated cells (0.42% ± 0.12%) ( Figure 4E ). On the contrary, a downregulation of 80% of Dlk1 expression in Lin 
DISCUSSION
Stem cell-specific expression of s-SHIP was initially identified in hematopoietic and embryonic stem cells (Rohrschneider et al., 2005; Tu et al., 2001) . Using s-SHIP-GFP promoter reporter, its stem cell-specific expression has been demonstrated in prostate tissues (Al Shareef et al., 2018; Bauderlique-Le Roy et al., 2015; Brocqueville et al., 2016) . In postnatal mammary gland development, GFP + cap cells in puberty and basal alveolar bud cells in pregnancy each exhibit stem cell properties (Bai and Rohrschneider, 2010 ). In the same study, the authors described the presence of GFP + tumor cells in heterogeneous luminal/basal-like mammary tumors originating in bitransgenic s-SHIP-GFP/MMTV-Wnt1 mice. Subsequent studies have demonstrated the value of s-SHIP promoter to investigate normal mammary stem cells (Huo and Macara, 2014; Kogata et al., 2013; Roarty et al., 2015 
GFP
À cells were injected subcutaneously into recipient SCID female mice in a limiting dilution manner. Mice were monitored until tumors were observed or up to 3 months if no tumors were detected. Tumor-initiating cell frequencies and p values were generated by ELDA. See also Figure S3E . (Bai and Rohrschneider, 2010) , together with an in-depth analysis of data for breast cancer from The Cancer Genome Atlas.
Transcriptional profiling showed few genes differentially expressed between Lin À CD49f + GFP + and Lin À CD49f + GFP À cells. Among them, the significant decrease of Dlk1 expression in GFP + cells has attracted our attention. DLK1 acts as a non-canonical ligand of the Notch signaling pathway and is expressed at a high frequency in various human tumors including breast carcinoma (Yanai et al., 2010) . Several studies have demonstrated that DLK1 can act as an inhibitor of Notch signaling in vitro, including in breast cancer cells (Nueda et al., 2017) . Our results strongly suggest that DLK1 acts as a negative regulator of stemness in breast cancer, which agrees with several studies pointing to a role of Notch pathway in breast cancer, especially in subtypes with stem-like features and endothelial-to-mesenchymal transition (Harrison et al., 2010) . Based on our results, we can hypothesize that DLK1 interacts with Notch receptor expressed by tumor cells and can act as a negative regulator of Notch activation and signaling in these tumors cells. It is likewise possible that DLK1 action implicates cells of the tumor microenvironment. Interestingly, a recent study showed that Notch ligand Dll1 mediates crosstalk between mammary stem cells and tissue-resident macrophages (Chakrabarti et al., 2018) . This implies that DLK1 may also be involved in the modulation of the oncogenic potential of mammary tumor cells through the inhibition of Notch signaling in surrounding macrophages. To address this issue, it would be important to determine the relationship between breast CSCs, macrophages, DLK1, and Notch signaling. Taken together, our results strongly support the relationship between mammary CSCs and s-SHIP expression. This is in accordance with high s-SHIP expression in murine claudin-low tumors that are enriched for CSC signature (Herschkowitz et al., 2012) . s-SHIP protein is a shorter isoform of SHIP1 protein that lacks the SH2 domain in its N-terminal region (Tu et al., 2001) . However, the function of s-SHIP protein remains unknown. SHIP2, the ubiquitous homolog of SHIP1, is crucial for maintaining the ER-negative breast CSCs through activation of Akt and JNK (Fu et al., 2014) . Since our data indicate s-SHIP as a potential clinical target for breast cancer therapy, the expression and role of s-SHIP in human breast cancers will be the subject of our future investigation.
EXPERIMENTAL PROCEDURES
All animal procedures were performed under a protocol (#01989.02) approved by the Animal Protocol Review Committees of the Institut Pasteur de Lille (France) in accordance with European regulation.
Statistics
Data are expressed as means ± SEM of at least three independent experiments. The statistical analysis was done by using two-way ANOVA or Student's t test with GraphPad Prism5, and a p value of <0.05 was considered significant. For in vivo tumor-initiating potential, the results were analyzed by extreme limiting dilution analysis (ELDA) (Hu and Smyth, 2009) .
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